Incipient and subclinical tuberculosis

A clinical review of early stages and progression of infection

Paul K. Drain, Kristina L. Bajema, David Dowdy, Keertan Dheda, Kogieleum Naidoo, Samuel G. Schumacher, Shuyi Ma, Erin Meermeier, David Lewinsohn, David R. Sherman

Research output: Contribution to journalReview article

22 Citations (Scopus)

Abstract

Tuberculosis (TB) is the leading infectious cause of mortality worldwide, due in part to a limited understanding of its clinical pathogenic spectrum of infection and disease. Historically, scientific research, diagnostic testing, and drug treatment have focused on addressing one of two disease states: latent TB infection or active TB disease. Recent research has clearly demonstrated that human TB infection, from latent infection to active disease, exists within a continuous spectrum of metabolic bacterial activity and antagonistic immunological responses. This revised understanding leads us to propose two additional clinical states: incipient and subclinical TB. The recognition of incipient and subclinical TB, which helps divide latent and active TB along the clinical disease spectrum, provides opportunities for the devel-opment of diagnostic and therapeutic interventions to prevent progression to active TB disease and transmission of TB bacilli. In this report, we review the current understanding of the pathogenesis, immunology, clinical epidemiology, diagnosis, treatment, and prevention of both incipient and subclinical TB, two emerging clinical states of an ancient bacterium.

Original languageEnglish (US)
Article numbere00021-18
JournalClinical Microbiology Reviews
Volume31
Issue number4
DOIs
StatePublished - Oct 1 2018

Fingerprint

Tuberculosis
Latent Tuberculosis
Infection
Allergy and Immunology
Research
Bacillus
Epidemiology
Bacteria
Mortality
Pharmaceutical Preparations

Keywords

  • Mycobacterium tuberculosis
  • Tuberculosis

ASJC Scopus subject areas

  • Epidemiology
  • Immunology and Microbiology(all)
  • Public Health, Environmental and Occupational Health
  • Microbiology (medical)
  • Infectious Diseases

Cite this

Drain, P. K., Bajema, K. L., Dowdy, D., Dheda, K., Naidoo, K., Schumacher, S. G., ... Sherman, D. R. (2018). Incipient and subclinical tuberculosis: A clinical review of early stages and progression of infection. Clinical Microbiology Reviews, 31(4), [e00021-18]. https://doi.org/10.1128/CMR.00021-18

Incipient and subclinical tuberculosis : A clinical review of early stages and progression of infection. / Drain, Paul K.; Bajema, Kristina L.; Dowdy, David; Dheda, Keertan; Naidoo, Kogieleum; Schumacher, Samuel G.; Ma, Shuyi; Meermeier, Erin; Lewinsohn, David; Sherman, David R.

In: Clinical Microbiology Reviews, Vol. 31, No. 4, e00021-18, 01.10.2018.

Research output: Contribution to journalReview article

Drain, PK, Bajema, KL, Dowdy, D, Dheda, K, Naidoo, K, Schumacher, SG, Ma, S, Meermeier, E, Lewinsohn, D & Sherman, DR 2018, 'Incipient and subclinical tuberculosis: A clinical review of early stages and progression of infection', Clinical Microbiology Reviews, vol. 31, no. 4, e00021-18. https://doi.org/10.1128/CMR.00021-18
Drain, Paul K. ; Bajema, Kristina L. ; Dowdy, David ; Dheda, Keertan ; Naidoo, Kogieleum ; Schumacher, Samuel G. ; Ma, Shuyi ; Meermeier, Erin ; Lewinsohn, David ; Sherman, David R. / Incipient and subclinical tuberculosis : A clinical review of early stages and progression of infection. In: Clinical Microbiology Reviews. 2018 ; Vol. 31, No. 4.
@article{255870c0da5f4c789e626fa55ce6b475,
title = "Incipient and subclinical tuberculosis: A clinical review of early stages and progression of infection",
abstract = "Tuberculosis (TB) is the leading infectious cause of mortality worldwide, due in part to a limited understanding of its clinical pathogenic spectrum of infection and disease. Historically, scientific research, diagnostic testing, and drug treatment have focused on addressing one of two disease states: latent TB infection or active TB disease. Recent research has clearly demonstrated that human TB infection, from latent infection to active disease, exists within a continuous spectrum of metabolic bacterial activity and antagonistic immunological responses. This revised understanding leads us to propose two additional clinical states: incipient and subclinical TB. The recognition of incipient and subclinical TB, which helps divide latent and active TB along the clinical disease spectrum, provides opportunities for the devel-opment of diagnostic and therapeutic interventions to prevent progression to active TB disease and transmission of TB bacilli. In this report, we review the current understanding of the pathogenesis, immunology, clinical epidemiology, diagnosis, treatment, and prevention of both incipient and subclinical TB, two emerging clinical states of an ancient bacterium.",
keywords = "Mycobacterium tuberculosis, Tuberculosis",
author = "Drain, {Paul K.} and Bajema, {Kristina L.} and David Dowdy and Keertan Dheda and Kogieleum Naidoo and Schumacher, {Samuel G.} and Shuyi Ma and Erin Meermeier and David Lewinsohn and Sherman, {David R.}",
year = "2018",
month = "10",
day = "1",
doi = "10.1128/CMR.00021-18",
language = "English (US)",
volume = "31",
journal = "Clinical Microbiology Reviews",
issn = "0893-8512",
publisher = "American Society for Microbiology",
number = "4",

}

TY - JOUR

T1 - Incipient and subclinical tuberculosis

T2 - A clinical review of early stages and progression of infection

AU - Drain, Paul K.

AU - Bajema, Kristina L.

AU - Dowdy, David

AU - Dheda, Keertan

AU - Naidoo, Kogieleum

AU - Schumacher, Samuel G.

AU - Ma, Shuyi

AU - Meermeier, Erin

AU - Lewinsohn, David

AU - Sherman, David R.

PY - 2018/10/1

Y1 - 2018/10/1

N2 - Tuberculosis (TB) is the leading infectious cause of mortality worldwide, due in part to a limited understanding of its clinical pathogenic spectrum of infection and disease. Historically, scientific research, diagnostic testing, and drug treatment have focused on addressing one of two disease states: latent TB infection or active TB disease. Recent research has clearly demonstrated that human TB infection, from latent infection to active disease, exists within a continuous spectrum of metabolic bacterial activity and antagonistic immunological responses. This revised understanding leads us to propose two additional clinical states: incipient and subclinical TB. The recognition of incipient and subclinical TB, which helps divide latent and active TB along the clinical disease spectrum, provides opportunities for the devel-opment of diagnostic and therapeutic interventions to prevent progression to active TB disease and transmission of TB bacilli. In this report, we review the current understanding of the pathogenesis, immunology, clinical epidemiology, diagnosis, treatment, and prevention of both incipient and subclinical TB, two emerging clinical states of an ancient bacterium.

AB - Tuberculosis (TB) is the leading infectious cause of mortality worldwide, due in part to a limited understanding of its clinical pathogenic spectrum of infection and disease. Historically, scientific research, diagnostic testing, and drug treatment have focused on addressing one of two disease states: latent TB infection or active TB disease. Recent research has clearly demonstrated that human TB infection, from latent infection to active disease, exists within a continuous spectrum of metabolic bacterial activity and antagonistic immunological responses. This revised understanding leads us to propose two additional clinical states: incipient and subclinical TB. The recognition of incipient and subclinical TB, which helps divide latent and active TB along the clinical disease spectrum, provides opportunities for the devel-opment of diagnostic and therapeutic interventions to prevent progression to active TB disease and transmission of TB bacilli. In this report, we review the current understanding of the pathogenesis, immunology, clinical epidemiology, diagnosis, treatment, and prevention of both incipient and subclinical TB, two emerging clinical states of an ancient bacterium.

KW - Mycobacterium tuberculosis

KW - Tuberculosis

UR - http://www.scopus.com/inward/record.url?scp=85052144789&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052144789&partnerID=8YFLogxK

U2 - 10.1128/CMR.00021-18

DO - 10.1128/CMR.00021-18

M3 - Review article

VL - 31

JO - Clinical Microbiology Reviews

JF - Clinical Microbiology Reviews

SN - 0893-8512

IS - 4

M1 - e00021-18

ER -